Published in Mol Immunol on April 26, 2005
Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs (2010) 1.89
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A (2012) 1.44
Antibody fragments: hope and hype. MAbs (2010) 1.42
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci U S A (2010) 1.18
Synthesis of bispecific antibodies using genetically encoded unnatural amino acids. J Am Chem Soc (2012) 1.14
Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol (2015) 1.09
Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia (2013) 1.05
World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA. MAbs (2012) 1.02
Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol (2013) 1.00
Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer (2009) 0.98
Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun (2012) 0.98
Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol (2014) 0.97
Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. Cancer Immunol Res (2013) 0.94
Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PLoS One (2010) 0.93
The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. PLoS One (2012) 0.91
Novel immunotherapies for hematologic malignancies. Immunol Rev (2015) 0.90
Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site. MAbs (2012) 0.88
Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6. Oncoimmunology (2015) 0.87
Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood (2015) 0.87
Self-assembled antibody multimers through peptide nucleic acid conjugation. J Am Chem Soc (2012) 0.86
Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. Int J Cancer (2014) 0.86
Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica (2013) 0.85
Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody. Cancer Immunol Res (2014) 0.84
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Rev Clin Pharmacol (2013) 0.84
Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia. Drug Des Devel Ther (2016) 0.83
Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells. J Hematol Oncol (2015) 0.82
T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell. Oncotarget (2014) 0.81
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol (2016) 0.81
Are BiTEs the "missing link" in cancer therapy? Oncoimmunology (2015) 0.81
Antibody-based immunotherapy for malignant glioma. Semin Oncol (2014) 0.80
Bispecific antibodies in cancer immunotherapy. Hum Vaccin Immunother (2016) 0.80
The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol (2016) 0.79
Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies. Expert Opin Biol Ther (2015) 0.78
Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8. PLoS One (2014) 0.78
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing. Cancer Cell (2017) 0.77
Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma. Oncoimmunology (2013) 0.77
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies. Int J Mol Sci (2016) 0.77
Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy. Theranostics (2015) 0.77
B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity. J Immunol (2015) 0.77
Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. Oncoimmunology (2015) 0.77
Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110. PLoS One (2015) 0.76
Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies. EMBO Mol Med (2017) 0.75
Rapid detection of hepatitis B virus surface antigen by an agglutination assay mediated by a bispecific diabody against both human erythrocytes and hepatitis B virus surface antigen. Clin Vaccine Immunol (2007) 0.75
CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1(+) tumor cells, and extends the survival of tumor-bearing humanized mice. Oncotarget (2017) 0.75
Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab. Onco Targets Ther (2017) 0.75
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (2008) 5.30
Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol (2009) 4.05
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood (2012) 3.38
The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res (2009) 3.25
High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol (2005) 2.54
Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol (2002) 2.48
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer (2005) 1.77
CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol (2006) 1.69
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol (2005) 1.69
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today (2005) 1.54
Blinatumomab: a historical perspective. Pharmacol Ther (2012) 1.52
Detection of melanoma antigen-A expression in sputum and bronchial lavage fluid of patients with lung cancer. Chest (2004) 1.46
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res (2011) 1.42
On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer (2009) 1.41
Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol (2013) 1.39
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother (2007) 1.30
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer (2002) 1.30
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology (2009) 1.28
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res (2005) 1.28
BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther (2009) 1.27
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer (2002) 1.26
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother (2010) 1.19
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci U S A (2010) 1.18
EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res (2011) 1.16
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood (2013) 1.16
Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer Res (2007) 1.15
A revival of bispecific antibodies. Trends Biotechnol (2004) 1.11
Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J (2004) 1.10
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother (2009) 1.08
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother (2007) 1.08
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother (2005) 1.05
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma (2009) 1.05
A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J Immunol (2003) 1.03
Antibody recognition of a unique tumor-specific glycopeptide antigen. Proc Natl Acad Sci U S A (2010) 1.00
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. Cancer Immunol Immunother (2005) 0.99
Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy. Cancer Immunol Immunother (2004) 0.97
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int (2010) 0.96
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother (2009) 0.96
Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PLoS One (2010) 0.93
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther (2012) 0.91
Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res (2008) 0.91
The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. PLoS One (2012) 0.91
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res (2008) 0.90
Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells. J Cancer Res Clin Oncol (2003) 0.90
Expression of epithelial cellular adhesion molecule (Ep-CAM) in chronic (necro-)inflammatory liver diseases and hepatocellular carcinoma. Hepatol Res (2005) 0.89
A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. Mol Immunol (2006) 0.89
Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells. J Immunother (2011) 0.87
Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties. Mol Pharmacol (2004) 0.87
Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo. Int Immunol (2003) 0.86
Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSF. Eur J Pharmacol (2006) 0.85
The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture. Liver Int (2012) 0.84
Bispecific antibodies for polyclonal T-cell engagement. Curr Opin Mol Ther (2003) 0.84
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans. Cancer Immunol Immunother (2008) 0.84
Identification of essential regions in the cytoplasmic tail of interleukin-1 receptor accessory protein critical for interleukin-1 signaling. J Biol Chem (2002) 0.84
A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur J Cancer (2006) 0.83